Office

Level 9, Suite 1, 68 Pitt Street,
Sydney, NSW, 2000, Australia

+61 (02) 8964 7401

info@actinogen.com.au

Social Media
 

ACW Investor Centre

ACW Newsletters & Reports

Actinogen Medical is a publicly listed (ASX: ACW) clinical-stage biotechnology company undertaking research in Alzheimer’s disease and other chronic neurodegenerative diseases. Below are links to some of our recent news and events.

Investor Presentation – March 2017

ACW Quarterly Newsletter – March 2017

The world love melbourne is a blog that recently wrote about Actinoge's Understanding Alzheimer's eventXanamemTM Research Presentation by Prof. Craig Ritchie at CTAD San Diego – 9 Dec 2016

Baker Young Research Update on ACW

Baker Young establishes updated research on Actinogen Medical in SeptemberBaker Young Research Update on ACW

Dr. Bill Ketelbey interviews with Wholesale Investor in SeptemberDr. Bill Ketelbey Interview with Wholesale Investor

The company has published the 5th volume of its newsletterACW Newsletter August 2016

Actinogen held a Symposium in september and this is the contents of that eventUnderstanding Alzheimer’s Symposium Program

This is the presentation given by Dr. Bill Ketelbey on 21 September, 2016 in Melbourne at the Novotel for the ACW Understanding Alzheimer's SymposiumDr. Bill Ketelbey Presentation for ACW Symposium

RedChip Research Report on ACWRedChip Research Report

December 2015 ACW Investor UpdateInvestor Update December 2015

Baker Young Initiation of Coverage for ACWBY Initiation of Coverage

ACW is developing Xanamem for ADCortisol Hypothesis Investor Presentation

ACW Investor Update from August 2015Investor Update August 2015

ACW 2015 AGM PresentationAGM Presentation 2015

ACW Investor Update from February 2015Investor Update February 2015

ASX Share Price

Actinogen Medical Ltd (ASX:ACW)

ASX Announcements

June
May
April
March
February
January
December
November
October
September

29 Sept 2016 – FDA Feedback on XanADu
05 Sept 2016 – R&D Tax Rebate
01 Sept 2016 – Investor Update Newsletter

August
July
June
May
April

14 Apr 2016 – Appendix 4C – Quarterly

March
February

19 Feb 2016 – Appendix 4D
09 Feb 2016 – R&D Tax Rebate

January

04 Jan 2016 – Appendix 3Y

December

01 Dec 2015 – Investor Update

November

17 Nov 2015 – Change of Company Name
12 Nov 2015 – Results of AGM
12 Nov 2015 – CEO’s AGM Presentation
12 Nov 2015 – Chairman’s AGM Address
06 Nov 2015 – Release of Securities from Voluntary Escrow

October
September
August
July
June
May
April

30 Apr 2015 – Share Purchase Plan
28 Apr 2015 – Change in Substantial Shareholding
27 Apr 2015 – Change in Substantial Shareholding
24 Apr 2015 – Ethics Approval Granted for Second Stage Phase I
24 Apr 2015 – Successful Capital Raising
24 Apr 2015 – Appendix 4C: Quarterly
22 Apr 2015 – Trading Halt
16 Apr 2015 – Clinical Trial Update
16 Apr 2015 – XCAB Conference Call Transcript
15 Apr 2015 – Investor Update
13 Apr 2015 – EU Patent Granted
13 Apr 2015 – Investor Presentation
13 Apr 2015 – XCAB Conference Call

March
February
January
December

18 Dec 2014 – ACW Board Changes
18 Dec 2014 – Appendix 3Z
18 Dec 2014 – Appendix 3X
15 Dec 2014 – Notice 708A
15 Dec 2014 – Appendix 3B
15 Dec 2014 – ACW Appoints Dr. Bill Ketelbey as CEO

ACW Corporate Partners

Subscribe to our newsletter

Are you an Investor?  Yes